TY - BOOK ID - 101913025 TI - Novel Anti-cancer Agents and Cellular Targets and Their Mechanism(s) of Action PY - 2022 SN - 3036552227 3036552219 PB - MDPI - Multidisciplinary Digital Publishing Institute DB - UniCat KW - Technology: general issues KW - History of engineering & technology KW - microtubule acetylation KW - triple-negative breast cancer KW - anti-cancer agent KW - apoptosis KW - K562 KW - 8-hydroxydaidzein KW - autophagy KW - BCR-ABL KW - MAPK KW - NF-κB KW - c-myc KW - RNA interference KW - siRNA KW - oncogene KW - gene silencing KW - expression KW - nanosystems KW - Cytochrome P450 KW - CYP1A1 KW - CYP1B1 KW - CYP2W1 KW - breast cancer KW - prodrug KW - bioprecursor KW - duocarmycin KW - phortress KW - AQ4N KW - 5-FU resistance KW - colorectal cancer KW - drug repurposing KW - Genomics of Drug Sensitivity in Cancer KW - Connectivity Map KW - anticancer drug KW - B-lactam steroid alkylators KW - synthetic lethality KW - poly (ADP-ribose) polymerase inhibitors KW - ovarian cancer KW - hybrid steroidal alkylating agents KW - migration KW - invasion KW - glioblastoma KW - CCN1 KW - mesenchymal–amoeboid transition KW - biomarker KW - HepG2 KW - Huh7 KW - isatin sulfonamides KW - angiogenesis KW - cancer hallmarks KW - molecular docking KW - EGFR tyrosine kinase inhibitor KW - photon upconversion KW - triplet-triplet annihilation KW - in vivo imaging KW - PLGA KW - nanoparticles KW - affibody molecule KW - human epidermal growth factor receptor 3 (HER3) KW - BxPC-3 KW - emtansine KW - DM1 KW - albumin binding domain KW - affibody drug conjugate (AffiDC) KW - n/a KW - mesenchymal-amoeboid transition UR - https://www.unicat.be/uniCat?func=search&query=sysid:101913025 AB - Patient outcomes remain poor for many cancers despite improvements in treatments and new molecular-targeted biomedicines for certain cancer types or subtypes. Dose-limiting toxicity, a narrow therapeutic index, and the development of resistance to traditional anti-cancer agents are well-established. It is apparent that inherent and acquired drug resistance are major challenges with molecular-targeted agents and that on- as well as off-target side effects can still occur. Other issues include drug metabolism by the body and safely supplying a sufficient amount of active drug to the tumor cells. There is a clear and urgent need for new molecular targets and drugs that specifically target cancer cells in different ways to existing approved drugs. This book, through a collection of eight research articles and two review articles from the Biomedicines themed Special Issue ‘Novel Anti-Cancer Agents and Cellular Targets and Their Mechanism(s) of Action’, provides a snapshot of some of the diverse and exciting research approaches being taken by the cancer research community in trying to address some of these therapeutic challenges. ER -